Karuppiah Kannan

1.9k citations

29 papers · 1.1k indexed · h-index 13

Co-authors: David Givol Gideon Rechavi Ninette Amariglio Naftali Kaminski Lynda Chin Norman E. Sharpless Eytan Domany Itai Kela
Topics: Cancer-related Molecular Pathways (6 papers)Fibroblast Growth Factor Research (4 papers)PI3K/AKT/mTOR signaling in cancer (3 papers)
Cited by: Oncology Molecular Biology Cancer Research
Journals: Proceedings of the National Academy of Sciences Nature Communications Journal of Clinical Oncology
Partner nations: United States Israel Japan

In The Last Decade

Karuppiah Kannan

28 papers receiving 1.1k citations

Peers

Countries citing papers authored by Karuppiah Kannan

Since Specialization

Citations

This map shows the geographic impact of Karuppiah Kannan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karuppiah Kannan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karuppiah Kannan more than expected).

Fields of papers citing papers by Karuppiah Kannan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karuppiah Kannan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karuppiah Kannan. The network helps show where Karuppiah Kannan may publish in the future.

Co-authorship network of co-authors of Karuppiah Kannan

This figure shows the co-authorship network connecting the top 25 collaborators of Karuppiah Kannan. A scholar is included among the top collaborators of Karuppiah Kannan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karuppiah Kannan. Karuppiah Kannan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockade 2023 ·Nature Communications ·Tomoko Morita,Jie Yu,Yukie Kashima,Ryo Kamata,Gaku Yamamoto,Tatsunori Minamide,(unknown),(unknown),(unknown),(unknown),(unknown),Shun‐Ichiro Kageyama,(unknown),Eric S. Lightcap,Kosuke Tanaka,Huifeng Niu,Karuppiah Kannan,Akihiro Ohashi	12
2	A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia 2022 ·Haematologica ·Keith W. Pratz,Jason Kaplan,Moshe Levy,Dale L. Bixby,Patrick W. Burke,Harry P. Erba,Trisha M. Wise‐Draper,Gail J. Roboz,Nikolaos Papadantonakis,Trivikram Rajkhowa,Daniela Hernandez,(unknown),Richard C. Gregory,Cheryl Li,Shining Wang,(unknown),Karuppiah Kannan,Harry Miao,Mark J. Levis	10
3	A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery 2021 ·Science Advances ·Kenichi Iwai,Tadahiro Nambu,Yukie Kashima,Jie Yu,(unknown),Kazumasa Miyamoto,(unknown),(unknown),Toshiyuki Takeuchi,Akifumi Kogame,(unknown),Saomi Murai,Hiroshi Haeno,Shun‐Ichiro Kageyama,Osamu Kurasawa,Huifeng Niu,Karuppiah Kannan,Akihiro Ohashi	19
4	A phase 1b study to evaluate TAK-659 in combination with nivolumab in patients (pts) with advanced solid tumors. 2017 ·Journal of Clinical Oncology ·Dejan Juric,Stephanie Faucette,Ling Wang,Huifeng Niu,Karuppiah Kannan,(unknown),(unknown),Yaping Shou,John Nemunaitis	1
5	a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) 2016 ·Blood ·Jason Kaplan,Dale L. Bixby,John C. Morris,Olga Frankfurt,Jessica K. Altman,Trisha M. Wise‐Draper,Patrick W. Burke,(unknown),Karuppiah Kannan,Ling Wang,Stephanie Faucette,Benjamin J. Lee,Yaping Shou,Mark J. Levis,Keith W. Pratz	10
6	Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib) 2014 ·Molecular Cancer Therapeutics ·Jessica J. Huck,Mengkun Zhang,Jerome T. Mettetal,Arijit Chakravarty,Karthik Venkatakrishnan,Xiaofei Zhou,(unknown),Marc L. Hyer,Karuppiah Kannan,Vaishali Shinde,(unknown),Mark Manfredi,Wen Chyi Shyu,Jeffrey Ecsedy	27
7	Antitumor activity of inhibiting SYK kinase with TAK-659, an investigational agent, in DLBCL models. 2014 ·Journal of Clinical Oncology ·Jessica J. Huck,Rachael Brake,(unknown),Helen He,Matthew Theisen,Jie Yu,Mengkun Zhang,Suresh K. Balani,Josephine M. Atienza,Patrick W. Vincent,Mark Manfredi,Jonathan Zalevsky,Karuppiah Kannan	4
8	Mitochondrial DNA variation in the endangered fish Dawkinsia tambraparniei (Actinopterygii: Cypriniformes: Cyprinidae) from southern Western Ghats, India 2014 ·Acta Ichthyologica Et Piscatoria ·Karuppiah Kannan,Jeyaraj Antony Johnson,(unknown),Sandeep Kumar Gupta	0
9	De novo Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model 2009 ·Cancer Research ·James Watters,Chun Cheng,Pradip K. Majumder,Ruojie Wang,Sireesha Yalavarthi,Carol Meeske,Lingxin Kong,Wenping Sun,Jie Lin,Joerg Heyer,Chris Ware,Christopher Winter,John F. Reilly,Tim Demuth,(unknown),M. Isabel Chiu,Murray O. Robinson,Nancy E. Kohl,Karuppiah Kannan	31
10	Abstract A233: Generation of in vitro and in vivo tumor models driven by insulin-like growth factor receptor (IGF1R) and their use in the development of OSI-906, a selective IGF1R inhibitor 2009 ·Molecular Cancer Therapeutics ·Qing Liu,(unknown),Nianjun Tao,Lu Huang,John Yang,Brian Krieger,Elizabeth Buck,Ruojie Wang,Karuppiah Kannan,M. Isabel Chiu,Murray O. Robinson	1
11	Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo 2003 ·Oncogene ·Norman E. Sharpless,Karuppiah Kannan,Jin Xu,Marcus Bosenberg,Lynda Chin	77
12	Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model 2003 ·Proceedings of the National Academy of Sciences ·Karuppiah Kannan,Norman E. Sharpless,Jin Xu,Rónán C. O’Hagan,Marcus Bosenberg,Lynda Chin	90
13	Array comparative genome hybridization for tumor classification and gene discovery in mouse models of malignant melanoma. 2003 ·PubMed ·Rónán C. O’Hagan,Cameron Brennan,Andrew Strahs,Xuegong Zhang,Karuppiah Kannan,(unknown),(unknown),Norman E. Sharpless,Wing Hung Wong,Lynda Chin	31
14	A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1 2002 ·Oncogene ·Galit Rozenfeld-Granot,Janakiraman Krishnamurthy,Karuppiah Kannan,Amos Toren,Ninette Amariglio,David Givol,Gideon Rechavi	56
15	DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1 2001 ·Oncogene ·Karuppiah Kannan,Naftali Kaminski,Gideon Rechavi,(unknown),Ninette Amariglio,David Givol	127
16	DNA microarrays identification of primary and secondary target genes regulated by p53 2001 ·Oncogene ·Karuppiah Kannan,Ninette Amariglio,Gideon Rechavi,(unknown),Itai Kela,Naftali Kaminski,Gad Getz,Eytan Domany,David Givol	276
17	Apoptosis of Granulosa Cells and Female Infertility in Achondroplastic Mice Expressing Mutant Fibroblast Growth Factor Receptor 3G374R 2001 ·Molecular Endocrinology ·Abraham Amsterdam,Karuppiah Kannan,David Givol,Yoshio Yoshida,Kimihisa Tajima,Ada Dantes	16
18	Profile of gene expression regulated by induced p53: connection to the TGF‐β family 2000 ·FEBS Letters ·Karuppiah Kannan,Ninette Amariglio,Gideon Rechavi,David Givol	89
19	FGF Receptor Mutations: Dimerization Syndromes, Cell Growth Suppression, and Animal Models 2000 ·IUBMB Life ·Karuppiah Kannan,David Givol	36
20	A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3 1999 ·Proceedings of the National Academy of Sciences ·Yingcai Wang,(unknown),Karuppiah Kannan,(unknown),Aaron Avivi,Marat Gorivodsky,Mark Pines,Avner Yayon,Peter Lonai,David Givol	181

About Karuppiah Kannan

Karuppiah Kannan is a scholar working on Aging, Oncology and Aquatic Science, having authored 29 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (6 papers), Fibroblast Growth Factor Research (4 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). The work is most often cited by research in Oncology (427 citations), Molecular Biology (831 citations) and Cancer Research (146 citations). Karuppiah Kannan has collaborated with scholars based in United States, Israel and Japan. Frequent co-authors include David Givol, Gideon Rechavi, Ninette Amariglio, Naftali Kaminski, Lynda Chin, Norman E. Sharpless, Eytan Domany, Itai Kela, Gad Getz and Marcus Bosenberg. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact